Therapeutic use of anti-TF-Antigen antibody
View Patent ↗The invention is related to administration of monoclonal antibody JAA-F11 to an individual for inhibition of metastasis and/or inhibition of growth of cells which express TF-Ag, or for detection of tumors or metastatic foci which express TF-Ag. For inhibition of metastasis or inhibition of growth of cells expressing TF-Ag, the method comprises administering to the individual a therapeutic amount of mAb JAA-F11, wherein the JAA-F11 mAb inhibits the metastasis and/or growth of the TF-Ag expressing cancer cells. For detection of tumors or metastatic foci, mAb JAA-F11 is conjugated to a detectable label and administered to the individual. Detection of the label identifies metatstatic foci or tumors which comprise cancer cells expressing TF-Ag.
1. A method for inhibiting in an individual metastasis of metastatic tumor cells, wherein the metastatic tumor cells express TF-Ag molecules, comprising administering to the individual an amount of monoclonal antibody JAA-F11 or an antigen binding fragment thereof sufficient to inhibit the metastasis of the metastatic tumor cells expressing the TF-Ag molecules, such that the metastasis of the cells expressing the TF-Ag molecules is inhibited.
2. The method of claim 1 , wherein the antigen binding fragment is selected from the group consisting of Fab, Fab′, F(ab′) 2 , and Fv.
3. The method of claim 1 , wherein the cells expressing the TF-Ag molecules are selected from the group consisting of breast cancer cells, lung cancer cells, prostate cancer cells and pancreas cancer cells.
4. The method of claim 1 , wherein the monoclonal antibody JAA-F11 is humanized.
5. The method of claim 1 , wherein the monoclonal antibody JAA-F11 is conjugated to an agent selected from the group consisting of toxins and radioactive isotopes.
6. The method of claim 5 , wherein the toxin is selected from the group consisting of diphtheria A chain and ricin A chain.
7. The method of claim 5 , wherein the radioactive isotope is selected from the group consisting of, I 123 , I 125 I 124 and I 131 .
8. The method of claim 1 , wherein the monoclonal antibody JAA-F11 is administered simultaneously or sequentially with a chemotherapeutic agent.
9. The method of claim 1 , wherein the monoclonal antibody JAA-F11 is administered by a route selected from the group consisting of parenteral, subcutaneous, intraperitoneal, intravenous, intralymphatic and intrapulmonary administration.
10. The method of claim 1 , wherein the metastatic tumor cells are carcinoma cells.